A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Human Mammary Carcinoma
Interventions: DRUG: AEG35156
Sponsor: Aegera Therapeutics